NephroGenex, Inc. (NRX) [Rocket]

In millions, except per share items	Dec-31-15	Dec-31-14	Dec-31-13	Dec-31-12	Dec-31-11
	10-K	10-K	10-K	S-1/A	S-1/A
Revenues	0.0	0.0	0.0	2.4	2.1
Revenue growth			-100.0%	9.8%
Cost of goods sold	0.0	0.0	0.0	2.4	2.1
Gross profit	0.0	0.0	0.0	0.0	0.0
Gross margin				0.0%	0.0%
Selling, general and administrative [+]	7.0	5.3	1.0	0.3	0.5
General and administrative	7.0	5.3	1.0	0.3	0.5
Research and development	15.3	11.3	1.5
Other operating expenses				2.4	2.1
EBITDA [+]	-22.3	-16.6	-2.5	-2.7	-2.6
EBITDA growth	34.5%	562.8%	-6.7%	3.0%
EBITDA margin				-114.0%	-121.5%
Depreciation and amortization	0.0	0.0	0.0	0.0	0.0
EBIT [+]	-22.3	-16.6	-2.5	-2.7	-2.6
EBIT growth	34.6%	561.9%	-7.2%	2.9%
EBIT margin				-114.9%	-122.5%
Interest expense, net [+]	0.5	0.1	0.4	0.2	0.1
Interest expense	0.6	0.1	0.4	0.2	0.1
Interest income	0.0	0.0	0.0	0.0	0.0
Other income (expense), net [+]		-0.1	-3.4	0.0	0.8
Change in fair value of warrants		-0.1	-3.4
Pre-tax income	-22.9	-16.8	-6.3	-2.9	-1.9
Income taxes	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-22.9	-16.8	-6.3	-2.9	-1.9
Net margin				-123.5%	-86.4%

Basic EPS [+]	($2.29)	($2.15)	($19.71)	($9.08)	($5.79)
Growth	6.3%	-89.1%	117.1%	56.8%
Diluted EPS [+]	($2.29)	($2.15)	($19.71)	($9.08)	($5.79)
Growth	6.3%	-89.1%	117.1%	56.8%

Shares outstanding (basic) [+]	10.0	7.8	0.3	0.3	0.3
Growth	27.8%	2347.0%	0.0%	0.0%
Shares outstanding (diluted) [+]	10.0	7.8	0.3	0.3	0.3
Growth	27.8%	2347.0%	0.0%	0.0%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.